Why the study?
Do non-immune therapies such as ACE inhibitors, fish oil, and antiplatelet agents improve renal outcomes in patients with IgA glomerulonephritis?
Population
Patients with IgA glomerulonephritis (IgAGN)
Design
Review
Authors
Loading...
ACE inhibitors and adjuncts may reduce proteinuria in IgA nephropathy; leaves open confirmation in prospective RCTs.
Do non-immune therapies such as ACE inhibitors, fish oil, and antiplatelet agents improve renal outcomes in patients with IgA glomerulonephritis?
Non-immune therapies, particularly ACE inhibitors, fish oil, and combined antiplatelet/anticoagulation therapy, offer renoprotective benefits in patients with IgA glomerulonephritis by targeting the common pathway of progressive renal injury.
Ignatius K.P. Cheng (1997) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: